Clinical trials: Hepatic Neoplasm
HepatoCellular Carcinoma
Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment
The purpose of this study is to evaluate whether statin could prevent recurrence of hepatocellular carcinoma after curative treatment
- Trial name
- SHOT (NCT03024684)
- Testing
- Atorvastatin
- Where
- 6 sites in Taiwan
- Volunteers
- 240 people
- Sponsor
- Chiayi Christian Hospital
Hepatocellular Carcinoma
The Efficacy of Sequential RT After Triple Therapy for uHCC
Triple therapy of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies has demonstrated excellent efficacy in unresectable hepatocellular carcinoma (uHCC).
- Trial name
- NCT07052448
- Testing
- sequential radiotherapy after the combination of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Fujian Provincial Hospital
Hepatocellular Carcinoma (HCC)
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma
This study is to evaluate the safety, tolerability, efficacy and immunogenicity of RZ-001 in combination with Valganciclovir (VGCV) and Atezolizumab/Bevacizumab when given to subjects with human telomerase reverse transcriptase…
- Trial name
- NCT06695026
- Testing
- RZ-001 Dose 1, RZ-001 Dose 2, RZ-001 Dose 3
- Where
- 9 sites in South Korea
- Volunteers
- 45 people
- Sponsor
- Rznomics, Inc.
Carcinoma, Hepatocellular, Liver Neoplasms
RCT of Screening Strategies Among Patients at High Risk for Developing HCC in a Safety-net Health System
Hepatocellular carcinoma (HCC) is the 9th leading cause of cancer-related death in the US and one of the leading causes of death in patients with cirrhosis.
- Trial name
- NCT02312817
- Testing
- Mailed Outreach Invitation, Mailed Outreach Invitation and Patient Navigation
- Where
- United States
- Volunteers
- 1,800 people
- Sponsor
- University of Texas Southwestern Medical Center
Breast Cancer, Kidney Neoplasms
Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging
This is a 4-arm, single-center study involving 40 participants. Ten healthy volunteers will be enrolled for system imaging optimization, and thirty (30) patients with previously identified lesions in the breast, liver, or…
- Conditions
- Breast Cancer, Kidney Neoplasms, Liver Neoplasms
- Trial name
- NCT07225114
- Testing
- contrast agent perflutren lipid, Ultrasound Imaging
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hepatocellular Carcinoma
A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma
This study aims to evaluate the efficacy and safety of Sintilimab (an Anti-PD-1 Inhibitor) combined with apatinib and capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.
- Trial name
- NCT04411706
- Testing
- Sintilimab Combined With Apatinib and Capecitabine
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Xin-Hua Xu
Hepatocellular Carcinoma (HCC), Liver Cancer, Adult
An Innovative CFD-based Dosimetry and Pre-treatment Planning Platform to Support Personalized Transarterial Therapies for Liver Cancer
Transarterial radioembolization (TARE) is a key treatment option for patients with unresectable hepatocellular carcinoma (HCC), a primary form of liver cancer.
- Conditions
- Hepatocellular Carcinoma (HCC), Liver Cancer, Adult, Liver Cancer
- Trial name
- NCT07315633
- Testing
- Endovascular treatment
- Where
- Belgium
- Volunteers
- 80 people
- Sponsor
- University Hospital, Ghent
Liver Failure, Carcinoma, Hepatocellular
Remote Ischemic Conditioning (RIC) in Recipients of Brain Death Donor Livers - A Feasibility and Safety Study
This study will assess the feasibility of lower limb-ischemia induced Remote Ischemic Conditioning (RIC) in the perioperative period before, during, and after Orthotopic Liver Transplantation (OLT).
- Trial name
- NCT02635347
- Testing
- Remote Ischemic Conditioning (RIC), Pneumatic tourniquet
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Rutgers, The State University of New Jersey
Liver Cancer, Neoplasm Metastasis
A Trial Evaluating the Pharmacokinetics and Mode of Action of EndoTAG®-1 in Tumor Patients With Hepatic Metastases
The primary objective of study CT 4003 is to assess the behavior of EndoTAG®-1 in the body (making a so-called pharmacokinetic profile). Therefore, the course of the drug in the body is examined, i.e.
- Trial name
- NCT00542048
- Testing
- EndoTAG®-1
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- MediGene
Hepatocellular Carcinoma
A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
A study that aimed to assess the safety and anti-tumor activity of CCAR031 injection in unresectable HCC patients.
- Trial name
- NCT05155189
- Testing
- C-CAR031, Lenvatinib, Regorafenib (BAY 73-4506)
- Where
- 2 sites in China
- Volunteers
- 72 people
- Sponsor
- Zhejiang University
Hepatocellular Carcinoma (HCC), Cachexia
Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy
Primary Objective: To evaluate the effect of nanocrystalline megestrol acetate versus placebo on body weight and appetite in patients with unresectable hepatocellular carcinoma receiving TACE combined with targeted and…
- Conditions
- Hepatocellular Carcinoma (HCC), Cachexia, Anorexia, Malnutrition
- Trial name
- NCT07565415
- Testing
- Nanocrystalline megestrol acetate
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Type 2 Diabetes Mellitus, Obesity
The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes
This research study is being performed to begin to determine the effectiveness of two dominant bariatric surgery procedures versus an intensive lifestyle intervention to induce weight loss in patients and promote improvements in…
- Trial name
- TRIABETES (NCT01047735)
- Testing
- Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Pittsburgh
Intrahepatic Cholangiocarcinoma
Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations
Basilea provided expanded access to derazantinib for patients with locally advanced, inoperable or metastatic intrahepatic cholangiocarcinoma (iCCA) with FGFR genomic alterations on a patient by patient basis while clinical…
- Trial name
- NCT04087876
- Testing
- derazantinib
- Sponsor
- Basilea Pharmaceutica
Hepatic Neoplasms
Comparative Study on Liver Resection Between Harmonic Scalpel Versus Crush-clamping Method
Blood loss during liver resection significantly associates with short term operative outcome. The median blood loss during partial liver resection is 700-1200ml in high-volume centers.
- Trial name
- NCT02213692
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Hui-Chuan Sun
Hepatocellular Carcinoma (HCC), Immunotherapy
A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
This is a single-arm, multicenter, exploratory clinical study designed to evaluate the efficacy and safety of TACE combined with Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection in patients with unresectable…
- Conditions
- Hepatocellular Carcinoma (HCC), Immunotherapy, PD-1, CTLA-4
- Trial name
- NCT07128251
- Testing
- TACE treatment, Iparomlimab and Tuvonralimab Injection (QL1706), Bevacizumab
- Volunteers
- 47 people
- Sponsor
- Anhui Provincial Hospital
Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma
This phase I trial studies the side effects and best dose of RPCAR01 chimeric antigen receptor (CAR) T cells and to see how well it works in treating patients with GPC3 expressing hepatocellular carcinoma (HCC) that may have…
- Conditions
- Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma
- Trial name
- NCT06968195
- Testing
- Anti-GPC3-CAR Autologous T Lymphocytes, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Roswell Park Cancer Institute
Liver Cancer
Megestrol in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using megestrol may fight liver cancer by blocking the uptake of estrogen. It is not yet known if megestrol is an effective treatment for liver cancer.
- Trial name
- NCT00041275
- Testing
- megestrol acetate
- Where
- 12 sites in Bangladesh, Burma and 8 more
- Volunteers
- 300 people
- Sponsor
- National Medical Research Council (NMRC), Singapore
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic or…
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00003557
- Testing
- dolastatin 10
- Where
- 11 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of Chicago
Hepatocellular Carcinoma
Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma
This is an open-label, single arm, multicenter, Phase II clinical study to investigate the efficacy and safety profiles of autologous ATL administration in HCC patients after curative treatment.
- Trial name
- NCT05304481
- Testing
- ATL administration
- Where
- 14 sites in Taiwan
- Volunteers
- 95 people
- Sponsor
- Lukas Biomedical Inc.
Hepatocellular Carcinoma (HCC)
Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study
B-mode ultrasonography (B-US), a standard method of surveillance of hepatocellular carcinoma (HCC), has a fair sensitivity of 63% in detecting early stage HCC.
- Trial name
- NCT02188901
- Testing
- Sonazoid-enhanced ultrasonography
- Where
- South Korea
- Volunteers
- 523 people
- Sponsor
- Yonsei University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.